MD Anderson Cancer Center
The University of Texas
Houston, TX
Accepting patients
Olutasidenib
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
- IDH1 Inhibitor
- Phase 2
Not yet accepting
ELRiSE MDS
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (ELRiSE MDS)
- Activin Receptor IIA Inhibitor
- Randomization
- Phase 3
Accepting patients
RALLY-MF
RALLY-MF: A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and AnemiaA Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
- Monoclonal Antibody
- Hemojuvelin (HJV)
- Randomization
- Monotherapy
- Phase 1/2
- Has results
Accepting patients
IRAK
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
- IRAK 1 Inhibitor
- IRAK 4 Inhibitor
- Phase 1/2
- Has results
Accepting patients
REM-422
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
- MYB mRNA Degrader
- Phase 1
Accepting patients
BH-30236
A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- CLK Inhibitor
- Phase 1
Accepting patients
RENEW
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Activin Receptor IIA Inhibitor
- Closed Label (Masked)
- Placebo
- Phase 3
Accepting patients
Orca-Q
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
Lisaftoclax
A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).
- BCL-2 Inhibitor
- Randomization
- Placebo
- Phase 3
Accepting patients
BGB-11417
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
- BCL-2 Inhibitor
- Phase 1/2
- Has results